Some Observations on the more
important points made by
Miss Ellen Goudsmit PhD in her
“formal response” of 10th May 2005
to concerns about the ‘London’
criteria
Margaret Williams
11th May 2005
Background
The key
matter here at issue remains: why is the Medical Research Council (MRC)
intending to use the so-called “London” criteria for secondary analysis in the
PACE trials on “CFS/ME” when those criteria have not been defined or published
and when even the authors have not been established? How does this accord
with the MRC’s frequent claim of its requirement for (quote) “high scientific
standard” as contained in its press release and in its pro-forma replies to the
ME community (as, for example, in the letter of 15th April 2005 from
Simon Burden of the MRC to Neil Brown)?
The selection of participants for the PACE
trials is to be via the Oxford 1991 criteria which deliberately include those
with psychiatric disorders: however, by definition, those with a neurological
disorder are excluded from the Oxford criteria so one would assume that those
with myalgic encephalomyelitis (ME) would, by definition, be automatically
excluded from entry into the PACE trials. If there were to be strict
adherence to the entry criteria, this would indeed be so.
It seems that there is not to be strict
adherence to the Oxford criteria: Miss Goudsmit has stated --- correctly
--- that the psychiatrists involved with the PACE trials do not accept that ME
is a neurological disorder and on this basis those with ME will be
included in the PACE trials (presumably under the umbrella of “chronic
fatigue).
Miss Goudsmit maintains that because those with
ME will be included in the PACE trials, it is necessary for the MRC to use the
“London” criteria for secondary analysis to identify those with ME; that the
MRC will indeed use the “London” criteria has been publicly confirmed by Chris
Clark, CEO of AfME.
Is it not the case that if the MRC is serious
about using the “London” criteria in the PACE trials, it will first have to
issue and publish a pro-forma assessment sheet of the “London” criteria that
has been standardised for its researchers to use, and all groups of PACE
trial researchers will have to use the same criteria, and the criteria used in the
trials will have to be available and referenced?
Whilst desirous of an end to what might be
deemed unseemly squabbling in public, this is a matter of such grave concern
that it seems necessary to address some of the matters provided by Miss
Goudsmit in her “formal response”, because (even though she herself has removed
it from various internet sites) it remains in the public domain. For her
claims to be valid, they must be seen to stand up to scrutiny.
Miss Goudsmit refers to the “London” criteria
as “LC” and her “formal response” is in capital letters.
“(The LC) HAVE BEEN PUBLISHED ON THE
INTERNET….THEY HAVE NOT BEEN PUBLISHED IN A PEER-REVIEWED JOURNAL BUT NEITHER
WERE THE OTHERS”: it is the case that by convention, “publication” means
publication in a scientific journal. It is incorrect for Miss Goudsmit to
state that “the others” were not published in a peer-reviewed journal: both the
Holmes et al 1988 criteria and the Fukuda 1994 criteria were published in the
Annals of Internal Medicine, which is a peer-reviewed journal, with the Editors
selecting reviewers from a database of about 13,000 reviewers. It was only the
Oxford 1991 criteria (formulated mostly by psychiatrists) that were published
in a non peer-review journal (the Journal of the Royal Society of Medicine).
“GIVEN THE LC WERE FROMULATED (sic) FOR
IN-HOUSE USE AS OPPOSED TO GENERAL USE, THERE WAS NO NEED FOR THEM TO BE
PUBLISHED IN A JOURNAL AT THAT TIME”: “in-house use” means that the material
has not been published and is not available for general use; this being so,
other researchers would not use them because a) they would not know
anything about “in-house” criteria and b) other researchers would
not accept findings produced by “in-house” criteria without a published
reference to the specific criteria. If the “London” criteria were intended only
for limited “in-house” use by Action for ME and not for international
application, how would adding to the existing eight sets of criteria a further
set of criteria that were non-accessible to the international research
community advance understanding and lessen existing confusion? For Miss
Goudsmit to claim that the “London” criteria were intended only for “in-house”
use seems not to accord with what the Report of The National Task Force stated
about them in September 1994; it states that: “Action for ME, the ME
Association and The International Federation of ME Associations” (IFMEA)
proposed the “London” criteria. (IFMEA was created and run by Miss
Goudsmit herself as a means of collaboration between international ME
associations). If the “London” criteria were not intended for “GENERAL
USE” as here claimed by Miss Goudsmit, why does the National Task Force include
the International Federation of ME Associations” as one of the
proposers of the “London” criteria?
“THEY COULD NOT HAVE BEEN PUBLISHED EVEN IF WE
HAD WANTED TO, GIVEN THE BLANKET BAN ON ANYTHING POSITIVE REGARDING ME IN
BRITISH JOURNALS, THE ONLY JOURNALS WHO MIGHT HAVE BEEN INTERESTED”: If
the “London” criteria represented an advancement in defining those with ME, why
would they have been of interest only to British journals?
“SADLY, THE INFORMATION (in the Westcare
National Task Force Report) WAS NOT CHECKED WITH ANYONE WHO KNEW THE FACTS AND
WAS WRONG”: Is Miss Goudmsit implying that, because she thought of the
concept of the “London” criteria, only she knew the facts and was
able to check them? If so, given the eminence and experience of the
members of the Task Force (which included Dr William Weir, then of The Royal
Free Hospital and successor in post to Dr Melvin Ramsay), this is an
astonishing presumption by Miss Goudsmit. Neither Dr Anne Macintrye nor
Dr Charles Shepherd was a member of the Task Force but the Report acknowledged
their assistance, so it is presumed that they approved the
information regarding the “London” criteria contained within the Report.
(In her response to the claim that “Merely
being mentioned in a Report or published document does not equate with criteria
being published and used in research”): “THIS IS TRUE, BUT THEY WERE USED
IN RESEARCH”: unless the “London” criteria can be identified by virtue of
being defined, published and referenced, how can they be “used” as a credible
basis for research by anyone?
“IF IN 1994 YOU WANTED TO STUDY ME USING
RESEARCH CRITERIA, (the LC) WERE THE ONLY ONES AROUND, COMPILED BY SCIENTISTS
WITH A DEGREE OF EXPERTISE IN THE SUBJECT”: Is Miss Goudsmit referring to
herself as a “scientist with a degree of expertise in the subject”? The
reality is that Miss Goudsmit is not now and was not then in formal employment
in the field of ME and she has no professional clinical expertise in ME: she is
a patient who has degrees in psychology and she appears never to have held a
salaried post in the field in which she claims to be an expert. On her
own admission, she states that she has worked in clinics in a voluntary
capacity. Although qualified medical practitioners, neither
Dr Macintyre nor Dr Shepherd holds an NHS consultant post: Dr Macintyre worked
for a time as an eye surgeon in a third world country before succumbing to ME,
since when she has worked intermittently as a GP, and Dr Shepherd sees ME
patients privately at his home when not giving talks around the country as
Medical Adviser to the ME Association.
“THE CRITERIA WERE AS OPERATIONALISED AS OTHERS
AT THE TIME”: given that Miss Goudsmit herself states that the
“London” criteria were designed only for “in-house use”, how can it be true
that the “London” criteria were as widely “operationalised” as the Holmes et al
(1988) criteria, the Sharpe et al (Oxford 1991) criteria or the CDC (1994)
criteria?
“IF WILLIAMS BELIEVES (Dr Costa) USED DIFFERENT
CRITERIA (from the “London” criteria), CAN SHE PROVIDE A REFERENCE? A
COPY?”: the reference supplied by Costa et al confirms about the
population studied that “All ME/CFS patients were clinically assessed and
diagnosed according to standard criteria (Oxford), CDC and ME Action”.
The reference in the paper for the ME Action criteria is number 14.
That reference states: “Criteria for a diagnosis of ME for use in the
ME Action funded research. Based on the criteria suggested by WRC Weir in
Postviral Fatigue Syndrome by Jenkins & Mowbray pp 248-9”.
The Jenkins & Mowbray textbook at pp 248-249 sets out Dr Weir’s own
modification of the Holmes et al 1988 criteria and makes no mention of any
“London” criteria, nor of the authors of the criteria being Miss Goudsmit, Dr
Macintyre and Dr Shepherd. From this, it is apparent that the “ME Action”
criteria used by Costa, Tannock and Brostoff were based on criteria suggested
by Dr Weir. For comparison, in September 2004 Miss Goudsmit
stated about the use by Costa et al of the “London” criteria: “In the
Costa paper, the LC were listed as their ref 14. No full reference
because we don’t have major egos and at that time, did not insist people write
our names”, whilst in November 2004 Miss Goudsmit stated about the use of the
“London” criteria by Costa et al: “Costa did not refer to the criteria as the
LC but he did refer to the criteria developed by MEAction and guess what they
are?”. In her “formal response”, however, Miss Goudsmit now states: “IF
ONE COMPARES THE LC TO THOSE FROM WEIR, ONE SEES SOME NOTABLE DIFFERENCES.
NO-ONE COMPARING THEM WILL BE CONFUSED”. It must be emphasised that Costa
et al maintained that they had used the MEAction criteria, but Costa et
al referenced those MEAction criteria to Dr William Weir.
“I AM PLEASED THAT MS WILLIAMS HAS NOT REPEATED
THE ERROR THAT IT (ie. Miss Goudsmit’s dissertation) RECEIVED THE LOWEST SCORE,
AS IT DID NOT”: in the table published in JAMA, 19th September
2001:286:11:1360-1368, Miss Goudmsit’s dissertion was awarded 2 out of a
possible 20 points on the validity score; the paper by Perrin et al quoted by
Miss Goudsmit as having used the “London” criteria (which does indeed state
that participants were selected according to both the CDC and the “London”
criteria) scored 0 on the validity score. In relation to the Perrin et al
study, the lead author has confirmed to more than one person that he was
unaware that the “London” criteria had never been defined or published; he also
confirmed that he had relied entirely upon Drs Macintyre and Shepherd for
information about the “London” criteria; that it was Dr Macintyre who selected
patients for inclusion in his study from the database of members held by Action
for ME, and that it was Dr Macintyre who assured him that the “London” criteria
had been published and validated and that the reference for this was Costa et
al (QJM 1995) as asserted by Miss Goudsmit.
“PROF SCHOLEY WOULD HAVE TOLD ANYONE WHO
ENQUIRED THAT HE IS HOPING TO SUBMIT THIS STUDY FOR PUBLICATION. BUT THE
ISSUE I WAS ASKED TO ADDRESS WAS NOT, HAS THAT STUDY BEEN PUBLISHED, BUT DID IT
USE THE LC. IT DID!”: the question remains: how can anyone credibly
use criteria that have not even been defined and, since they remain
unpublished, are not available for comparison? If a researcher wanted to
publish the results, s/he would have no valid published reference point on
which to base the selection of patients for the study.
“ALL PATIENTS FULFILLED THE LC”: what are
the LC? Where (apart from the internet) can they be found? Who are
the authors? Where have they been published and made publicly available
for researchers’ use? Where are the comparative results of studies that
used them? What is their validity?
“ONE HAS TO FULFIL A NUMBER OF CRITERIA TO BE
CITED AS AUTHOR. YOU HAVE TO MAKE A SUBSTANTIAL CONTRIBUTION. I DID
NOT ACTUALLY WRITE A WORD OF THE LC BUT I WAS SUFFICIENTLY INVOLVED TO MERIT
INCLUSION AS AUTHOR. THE MRC WILL KNOW THE RULES.”: this should be compared
with what Miss Goudsmit states as being “ACCURATE” four paragraphs later:
“The London criteria are research criteria. I know this as I was one of
the co-authors”. Since the “London” criteria have never been published,
they have no authors as far as the outer world is concerned.
“I DID NOT SEE VERSION 2 (of the “London”
criteria) AND DO NOT KNOW WHO WROTE THEM”: who did write
“version 2” of the “London” criteria? What are the stipulated
criteria to which researchers must conform?
“PROF. WHITE IS AWARE OF THIS. AND IF HE
USES VERSION 2, I WILL NOT DEFEND HIM”: on what grounds is it Miss
Goudmit’s responsibility to “defend” Professor Peter White (lead researcher in
the MRC PACE trial)? If the “London” criteria are to be used, the MRC and
Professor Peter White should now issue a statement clarifying which version of
the “London” criteria they intend to use, and why, and should make available
the “London” criteria assessment sheet that will become the standard instrument
for use by all researchers for the PACE and FINE trials.
“IF MS WILLIAMS’ LOGIC IS EXTENDED TO MERGE,
ALL THEIR RESEARCH IS EQUALLY LACKING IN LEGITIMACY. IT IS BECAUSE WE
KNOW THEY USE ADDITIONAL CRITERIA, UNPUBLISHED, NOT PEER REVIEWED, THAT WE KNOW
THEY HAVE STUDIED ME”: for the avoidance of doubt, Dr Neil Abbot,
Director of Research at MERGE, has provided the following clarification:
“All patients were assessed by a medically qualified researcher to confirm that
they fulfilled the CDC 1994 criteria. Those that did not were excluded.
Additional measurements, for example, basic nerve function tests, were also
performed for subsequent comparisons but study entry was on the basis of
fulfilling the CDC 1994 criteria alone”.
Since Miss Goudsmit has provided no evidence
that the “London” criteria have been defined or published, and since they are
not on PubMed, it remains to be established how the MRC can justifiably use
them in the PACE trials. If, as she claims, the “London” criteria were
just for AfME’s in-house use, how can they legitimately be used for official
MRC research?
As things stand, the MRC trials would seem to
be open to potential abuse and the results to misinterpretation, but the two
major adult ME charities seem to be disinterested and even oblivious to this
possibility.